Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 193 to 202 of 202 entries
Sorted by: Best Match Show Resources per page
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.

The Prostate

Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann NC, Schuettfort VM, König F, Aydh A, Motlagh RS, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz PI, Briganti A, Shariat SF, Heidenreich A.
PMID: 34057227
Prostate. 2021 Aug;81(11):765-771. doi: 10.1002/pros.24173. Epub 2021 May 31.

PURPOSE: To examine the effect of lymph node dissection on the outcomes of patients who underwent salvage radical prostatectomy (SRP).MATERIAL AND METHODS: We retrospectively reviewed data from radiation-recurrent patients with prostate cancer (PCa) who underwent SRP from 2000-2016. None...

Cite
Quhal F, Rajwa P, Mori K, et al. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate. 2021;81(11):765-771doi: 10.1002/pros.24173.
Quhal, F., Rajwa, P., Mori, K., Laukhtina, E., Grossmann, N. C., Schuettfort, V. M., König, F., Aydh, A., Motlagh, R. S., Katayama, S., Mostafai, H., Pradere, B., Marra, G., Gontero, P., Mathieu, R., Karakiewicz, P. I., Briganti, A., Shariat, S. F., & Heidenreich, A. (2021). The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. The Prostate, 81(11), 765-771. https://doi.org/10.1002/pros.24173
Quhal, Fahad, et al. "The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer." The Prostate vol. 81,11 (2021): 765-771. doi: https://doi.org/10.1002/pros.24173
Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann NC, Schuettfort VM, König F, Aydh A, Motlagh RS, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz PI, Briganti A, Shariat SF, Heidenreich A. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate. 2021 Aug;81(11):765-771. doi: 10.1002/pros.24173. Epub 2021 May 31. PMID: 34057227; PMCID: PMC8361975.
Copy Download .nbib Format: NLM
Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.

International journal of clinical oncology

Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF.
PMID: 34757531
Int J Clin Oncol. 2022 Jan;27(1):59-71. doi: 10.1007/s10147-021-02061-0. Epub 2021 Nov 10.

Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in...

Cite
Yanagisawa T, Mori K, Katayama S, et al. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol. 2021;27(1):59-71doi: 10.1007/s10147-021-02061-0.
Yanagisawa, T., Mori, K., Katayama, S., Mostafaei, H., Quhal, F., Laukhtina, E., Rajwa, P., Motlagh, R. S., Aydh, A., König, F., Grossmann, N. C., Pradere, B., Miki, J., Kimura, T., Egawa, S., & Shariat, S. F. (2022). Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International journal of clinical oncology, 27(1), 59-71. https://doi.org/10.1007/s10147-021-02061-0
Yanagisawa, Takafumi, et al. "Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis." International journal of clinical oncology vol. 27,1 (2022): 59-71. doi: https://doi.org/10.1007/s10147-021-02061-0
Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol. 2022 Jan;27(1):59-71. doi: 10.1007/s10147-021-02061-0. Epub 2021 Nov 10. PMID: 34757531.
Copy Download .nbib Format: NLM
Best nonsurgical managements of acute urinary retention: what's new?.

Current opinion in urology

Baboudjian M, Peyronnet B, Boissier R, Robert G, Cornu JN, Misrai V, Pradere B.
PMID: 34954701
Curr Opin Urol. 2021 Dec 24; doi: 10.1097/MOU.0000000000000969. Epub 2021 Dec 24.

PURPOSE OF REVIEW: To provide a comprehensive review of the non-surgical management of acute urinary retention (AUR).RECENT FINDINGS: A recent meta-analysis confirmed that α-blockers are associated to higher rates of successful trial without catheter (TWOC) compared to placebo, while...

Cite
Baboudjian M, Peyronnet B, Boissier R, et al. Best nonsurgical managements of acute urinary retention: what's new?. Curr Opin Urol. 2021;doi: 10.1097/MOU.0000000000000969.
Baboudjian, M., Peyronnet, B., Boissier, R., Robert, G., Cornu, J. N., Misrai, V., & Pradere, B. (2021). Best nonsurgical managements of acute urinary retention: what's new?. Current opinion in urology, . https://doi.org/10.1097/MOU.0000000000000969
Baboudjian, Michael, et al. "Best nonsurgical managements of acute urinary retention: what's new?." Current opinion in urology vol. (2021). doi: https://doi.org/10.1097/MOU.0000000000000969
Baboudjian M, Peyronnet B, Boissier R, Robert G, Cornu JN, Misrai V, Pradere B. Best nonsurgical managements of acute urinary retention: what's new?. Curr Opin Urol. 2021 Dec 24; doi: 10.1097/MOU.0000000000000969. Epub 2021 Dec 24. PMID: 34954701.
Copy Download .nbib Format: NLM
SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors.

Bioorganic & medicinal chemistry letters

Yu W, Deng Y, Hopkins B, Huang X, Sloman D, Zhang H, Li D, McGowan MA, White C, Pu Q, Liu K, Fradera X, Lesburg CA, Martinot T, Doty A, Ferguson H, Nickbarg EB, Cheng M, Geda P, Song X, Smotrov N, Abeywickrema P, Andrews C, Chamberlin C, Mabrouk O, Curran P, Richards M, Saradjian P, Miller JR, Knemeyer I, Otte K, Vincent S, Sciammetta N, Bennett DJ, Han Y.
PMID: 34166782
Bioorg Med Chem Lett. 2021 Sep 01;47:128214. doi: 10.1016/j.bmcl.2021.128214. Epub 2021 Jun 21.

A novel series of IDO1 inhibitors have been identified with good IDO1 Hela cell and human whole blood activity. These inhibitors contain an indoline or a 3-azaindoline scaffold. Their structure-activity-relationship studies have been explored. Compounds 37 and 41 stood...

Cite
Yu W, Deng Y, Hopkins B, et al. SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. Bioorg Med Chem Lett. 2021;47:128214doi: 10.1016/j.bmcl.2021.128214.
Yu, W., Deng, Y., Hopkins, B., Huang, X., Sloman, D., Zhang, H., Li, D., McGowan, M. A., White, C., Pu, Q., Liu, K., Fradera, X., Lesburg, C. A., Martinot, T., Doty, A., Ferguson, H., Nickbarg, E. B., Cheng, M., Geda, P., Song, X., Smotrov, N., Abeywickrema, P., Andrews, C., Chamberlin, C., Mabrouk, O., Curran, P., Richards, M., Saradjian, P., Miller, J. R., Knemeyer, I., Otte, K., Vincent, S., Sciammetta, N., Bennett, D. J., & Han, Y. (2021). SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. Bioorganic & medicinal chemistry letters, 47128214. https://doi.org/10.1016/j.bmcl.2021.128214
Yu, Wensheng, et al. "SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors." Bioorganic & medicinal chemistry letters vol. 47 (2021): 128214. doi: https://doi.org/10.1016/j.bmcl.2021.128214
Yu W, Deng Y, Hopkins B, Huang X, Sloman D, Zhang H, Li D, McGowan MA, White C, Pu Q, Liu K, Fradera X, Lesburg CA, Martinot T, Doty A, Ferguson H, Nickbarg EB, Cheng M, Geda P, Song X, Smotrov N, Abeywickrema P, Andrews C, Chamberlin C, Mabrouk O, Curran P, Richards M, Saradjian P, Miller JR, Knemeyer I, Otte K, Vincent S, Sciammetta N, Bennett DJ, Han Y. SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. Bioorg Med Chem Lett. 2021 Sep 01;47:128214. doi: 10.1016/j.bmcl.2021.128214. Epub 2021 Jun 21. PMID: 34166782.
Copy Download .nbib Format: NLM
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.

Urologic oncology

Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NС, Rajwa P, Resch I, Enikeev D, Karakiewicz PI, Shariat SF, Schmidinger M.
PMID: 34400065
Urol Oncol. 2021 Nov;39(11):764-773. doi: 10.1016/j.urolonc.2021.07.022. Epub 2021 Aug 14.

PURPOSE: Tyrosine kinase inhibitors (TKIs) have been widely used in the management of patients with metastatic renal cell carcinoma (RCC). However, the use of systemic therapies in the adjuvant setting of localized and locally advanced RCC has shown conflicting...

Cite
Laukhtina E, Quhal F, Mori K, et al. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urol Oncol. 2021;39(11):764-773doi: 10.1016/j.urolonc.2021.07.022.
Laukhtina, E., Quhal, F., Mori, K., Sari Motlagh, R., Pradere, B., Schuettfort, V. M., Mostafaei, H., Katayama, S., Grossmann, N. �. �., Rajwa, P., Resch, I., Enikeev, D., Karakiewicz, P. I., Shariat, S. F., & Schmidinger, M. (2021). Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic oncology, 39(11), 764-773. https://doi.org/10.1016/j.urolonc.2021.07.022
Laukhtina, Ekaterina, et al. "Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis." Urologic oncology vol. 39,11 (2021): 764-773. doi: https://doi.org/10.1016/j.urolonc.2021.07.022
Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NС, Rajwa P, Resch I, Enikeev D, Karakiewicz PI, Shariat SF, Schmidinger M. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urol Oncol. 2021 Nov;39(11):764-773. doi: 10.1016/j.urolonc.2021.07.022. Epub 2021 Aug 14. PMID: 34400065.
Copy Download .nbib Format: NLM
Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada.

PloS one

Maharaj AS, Parker J, Hopkins JP, Gournis E, Bogoch II, Rader B, Astley CM, Ivers NM, Hawkins JB, Lee L, Tuite AR, Fisman DN, Brownstein JS, Lapointe-Shaw L.
PMID: 35015778
PLoS One. 2022 Jan 11;17(1):e0262447. doi: 10.1371/journal.pone.0262447. eCollection 2022.

BACKGROUND: Limitations in laboratory diagnostic capacity impact population surveillance of COVID-19. It is currently unknown whether participatory surveillance tools for COVID-19 correspond to government-reported case trends longitudinally and if it can be used as an adjunct to laboratory testing....

Cite
Maharaj AS, Parker J, Hopkins JP, et al. Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PLoS One. 2022;17(1):e0262447doi: 10.1371/journal.pone.0262447.
Maharaj, A. S., Parker, J., Hopkins, J. P., Gournis, E., Bogoch, I. I., Rader, B., Astley, C. M., Ivers, N. M., Hawkins, J. B., Lee, L., Tuite, A. R., Fisman, D. N., Brownstein, J. S., & Lapointe-Shaw, L. (2022). Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PloS one, 17(1), e0262447. https://doi.org/10.1371/journal.pone.0262447
Maharaj, Arjuna S, et al. "Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada." PloS one vol. 17,1 (2022): e0262447. doi: https://doi.org/10.1371/journal.pone.0262447
Maharaj AS, Parker J, Hopkins JP, Gournis E, Bogoch II, Rader B, Astley CM, Ivers NM, Hawkins JB, Lee L, Tuite AR, Fisman DN, Brownstein JS, Lapointe-Shaw L. Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PLoS One. 2022 Jan 11;17(1):e0262447. doi: 10.1371/journal.pone.0262447. eCollection 2022. PMID: 35015778.
Copy Download .nbib Format: NLM
Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada.

PloS one

Maharaj AS, Parker J, Hopkins JP, Gournis E, Bogoch II, Rader B, Astley CM, Ivers NM, Hawkins JB, Lee L, Tuite AR, Fisman DN, Brownstein JS, Lapointe-Shaw L.
PMID: 35015778
PLoS One. 2022 Jan 11;17(1):e0262447. doi: 10.1371/journal.pone.0262447. eCollection 2022.

BACKGROUND: Limitations in laboratory diagnostic capacity impact population surveillance of COVID-19. It is currently unknown whether participatory surveillance tools for COVID-19 correspond to government-reported case trends longitudinally and if it can be used as an adjunct to laboratory testing....

Cite
Maharaj AS, Parker J, Hopkins JP, et al. Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PLoS One. 2022;17(1):e0262447doi: 10.1371/journal.pone.0262447.
Maharaj, A. S., Parker, J., Hopkins, J. P., Gournis, E., Bogoch, I. I., Rader, B., Astley, C. M., Ivers, N. M., Hawkins, J. B., Lee, L., Tuite, A. R., Fisman, D. N., Brownstein, J. S., & Lapointe-Shaw, L. (2022). Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PloS one, 17(1), e0262447. https://doi.org/10.1371/journal.pone.0262447
Maharaj, Arjuna S, et al. "Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada." PloS one vol. 17,1 (2022): e0262447. doi: https://doi.org/10.1371/journal.pone.0262447
Maharaj AS, Parker J, Hopkins JP, Gournis E, Bogoch II, Rader B, Astley CM, Ivers NM, Hawkins JB, Lee L, Tuite AR, Fisman DN, Brownstein JS, Lapointe-Shaw L. Comparison of longitudinal trends in self-reported symptoms and COVID-19 case activity in Ontario, Canada. PLoS One. 2022 Jan 11;17(1):e0262447. doi: 10.1371/journal.pone.0262447. eCollection 2022. PMID: 35015778.
Copy Download .nbib Format: NLM
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.

European urology oncology

Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B.
PMID: 34753702
Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 06.

CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far.OBJECTIVE: To assess the diagnostic estimates of novel commercially...

Cite
Laukhtina E, Shim SR, Mori K, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021;4(6):927-942doi: 10.1016/j.euo.2021.10.003.
Laukhtina, E., Shim, S. R., Mori, K., D'Andrea, D., Soria, F., Rajwa, P., Mostafaei, H., Compérat, E., Cimadamore, A., Moschini, M., Teoh, J. Y., Enikeev, D., Xylinas, E., Lotan, Y., Palou, J., Gontero, P., Babjuk, M., Witjes, J. A., Kamat, A. M., Roupret, M., Shariat, S. F., Pradere, B. (2021). Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European urology oncology, 4(6), 927-942. https://doi.org/10.1016/j.euo.2021.10.003
Laukhtina, Ekaterina, et al. "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis." European urology oncology vol. 4,6 (2021): 927-942. doi: https://doi.org/10.1016/j.euo.2021.10.003
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 06. PMID: 34753702.
Copy Download .nbib Format: NLM
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.

Critical reviews in oncology/hematology

Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF.
PMID: 34902554
Crit Rev Oncol Hematol. 2022 Jan;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10.

OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis...

Cite
Laukhtina E, Sari Motlagh R, Mori K, et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2021;169:103570doi: 10.1016/j.critrevonc.2021.103570.
Laukhtina, E., Sari Motlagh, R., Mori, K., Katayama, S., Rajwa, P., Yanagisawa, T., Quhal, F., Mostafaei, H., Grossmann, N. C., König, F., Aydh, A., Pradere, B., Resch, I., Merseburger, A. S., Enikeev, D., & Shariat, S. F. (2022). Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical reviews in oncology/hematology, 169103570. https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina, Ekaterina, et al. "Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes." Critical reviews in oncology/hematology vol. 169 (2022): 103570. doi: https://doi.org/10.1016/j.critrevonc.2021.103570
Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. 2022 Jan;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10. PMID: 34902554.
Copy Download .nbib Format: NLM
Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis.

Arab journal of urology

Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, Shariat SF, Xylinas E, Baumeister P.
PMID: 33763246
Arab J Urol. 2020 Sep 04;19(1):31-36. doi: 10.1080/2090598X.2020.1817720.

OBJECTIVES: To compare oncological outcomes of open (ORNU) and laparoscopic radical nephroureterectomy (LRNU) after controlling for preoperative patient-derived factors.PATIENTS AND METHODS: We evaluated a multi-institutional collaborative database composed of 3984 patients diagnosed with upper tract urothelial carcinoma (UTUC) treated...

Cite
Moschini M, Zamboni S, Afferi L, et al. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. Arab J Urol. 2020;19(1):31-36doi: 10.1080/2090598X.2020.1817720.
Moschini, M., Zamboni, S., Afferi, L., Pradere, B., Abufaraj, M., Soria, F., D'Andrea, D., Roupret, M., De la Taille, A., Simeone, C., Mattei, A., Mathieu, R., Bensalah, K., Wirth, M. P., Montorsi, F., Briganti, A., Gallina, A., Simone, G., Gallucci, M., Di Bona, C., Marra, G., Mari, A., Di Trapani, E., Alvarez Maestro, M., Krajewski, W., Shariat, S. F., Xylinas, E., & Baumeister, P. (2020). Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. Arab journal of urology, 19(1), 31-36. https://doi.org/10.1080/2090598X.2020.1817720
Moschini, Marco, et al. "Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis." Arab journal of urology vol. 19,1 (2020): 31-36. doi: https://doi.org/10.1080/2090598X.2020.1817720
Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, Shariat SF, Xylinas E, Baumeister P. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. Arab J Urol. 2020 Sep 04;19(1):31-36. doi: 10.1080/2090598X.2020.1817720. PMID: 33763246; PMCID: PMC7954493.
Copy Download .nbib Format: NLM
Showing 193 to 202 of 202 entries